---
schema_version: "secwatch.filing_event.v1"
accession: "0000875045-25-000035"
form_type: "8-K"
ticker: "BIIB"
cik: "0000875045"
company_name: "BIOGEN INC."
filed_at: "2025-07-31T23:59:59+00:00"
generated_at: "2026-05-17T22:37:33.581380+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Biogen Q2 revenue $2.6B (+7% YoY), GAAP EPS $4.33, raises FY2025 guidance

## Summary
- Q2 2025 revenue $2.6B (+7% YoY); GAAP EPS $4.33 (+8%); Non-GAAP EPS $5.47 (+4%).
- Raised FY2025 Non-GAAP EPS guidance to $15.50-$16.00 (from $14.50-$15.50); revenue now expected ~flat vs 2024.
- LEQEMBI U.S. in-market sales ~$63M (+20% sequential); global ~$160M incl. $35M one-time China shipment.
- SKYCLARYS global rev. ~$130M; U.S. ~$78M (+13% seq.); ZURZUVAE $46M (+68% seq.).
- Pipeline: salanersen advancing to registrational stage in SMA; felzartamab Phase 3 initiated in rare kidney diseases.

## SEC filing metadata
- accession: 0000875045-25-000035
- form_type: 8-K
- ticker: BIIB
- cik: 0000875045
- company_name: BIOGEN INC.
- filed_at: 2025-07-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875045/000087504525000035/0000875045-25-000035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875045/000087504525000035/biib-20250731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000875045-25-000035
- JSON: https://secwatch.observer/filing/0000875045-25-000035.json
- Plain text: https://secwatch.observer/filing/0000875045-25-000035.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.